Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthy Living Europe.
Press releases published on August 6, 2025
Zevra Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference
GlobeNewswire
·
August 6, 2025
CELEBRATION, Fla., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that members of Zevra’s …
Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
August 6, 2025
Q2 total revenue of $10.7M includes previously-deferred revenue following reacquisition of Greater China rights to imdusiran Dr. Roger Sawhney joins the Arbutus Board of Directors following resignation of Anuj Hasija Dr. Harry Janssen joins the Arbutus …
Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates
GlobeNewswire
·
August 6, 2025
Partnership discussions for pilavapadin remain underway following Phase 2b PROGRESS study results IND-enabling studies of LX9851 for obesity and related disorders on track for completion in 2025 with licensee Novo Nordisk expected to submit IND Enrollment …
FDA Petition to Ban Mercury Dental Fillings submitted by IAOMT and DAMS INC.
GlobeNewswire
·
August 6, 2025
LAKELAND, Fla., Aug. 06, 2025 (GLOBE NEWSWIRE) -- The International Academy of Oral Medicine and Toxicology (IAOMT) and the Dental Amalgam Mercury Solutions (DAMS INC) have joined forces to petition the Food and Drug Administration (FDA) to ban mercury …
Arch Biopartners Announces First Patient Successfully Dosed at Toronto General Hospital in Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury
GlobeNewswire
·
August 6, 2025
First patient successfully completes dosing at Toronto General Hospital St. Michael’s Hospital is expected to be the next Canadian clinical site activated Arch is looking for additional clinical sites in North America to join the trial TORONTO, Aug. 06, …
Appili Therapeutics and Colleagues Publish Manuscript Demonstrating Efficacy of ATI-1701 Tularemia Vaccine
GlobeNewswire
·
August 6, 2025
Peer-reviewed publication highlights ATI-1701’s robust protection against aerosolized Francisella tularensis exposure in multiple animal models HALIFAX, Nova Scotia, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the …
MannKind and Blackstone Announce up to $500 Million Strategic Financing Agreement
GlobeNewswire
·
August 6, 2025
Strengthens MannKind’s capital structure with flexible, long-term, non-dilutive funding MannKind to receive $75 million in cash at closing DANBURY, Conn. and WESTLAKE VILLAGE, Calif. and NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation ( …
MannKind Corporation Reports Second Quarter 2025 Financial Results And Provides Business Update
GlobeNewswire
·
August 6, 2025
2Q 2025 revenues of $76.5M, +6% v. 2Q 2024 YTD 2025 revenues of $154.9M, +12% v. YTD 2024 Advanced pipeline: Submitted sBLA for Afrezza® in pediatric population MNKD-101: NTM global Phase 3 trial (ICoN-1) enrollment ahead of schedule MNKD-201: Plan to …
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
August 6, 2025
RESEARCH TRIANGLE PARK, N.C., Aug. 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 10 newly-hired employees stock options to purchase an …
FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine
GlobeNewswire
·
August 6, 2025
FDA approves single-dose AJOVY® (fremanezumab-vfrm) injection for the preventive treatment of episodic migraine in children and adolescents aged 6-17 who weigh 45 kilograms or more, offering a long-awaited monthly treatment option with in-office or at-home …
Kamada to Announce Second Quarter and First Half Ended June 30, 2025 Financial Results on August 13, 2025
GlobeNewswire
·
August 6, 2025
REHOVOT, Israel, and HOBOKEN, N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a …
EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments
GlobeNewswire
·
August 6, 2025
– Completed Phase 3 enrollment for DURAVYU™ in wet AMD with over 800 patients enrolled and randomized – – LUGANO and LUCIA trials each rapidly enrolled in seven months underscoring strong physician and patient interest – – Topline 56-week data for LUGANO …
Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025
GlobeNewswire
·
August 6, 2025
WEST CHESTER, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that …
BioXcel Therapeutics Announces Publication in Frontiers in Pharmacology on the Effects of Dexmedetomidine (the active ingredient in BXCL-501) on Stress-Mediated Behaviors in Non-clinical Studies
GlobeNewswire
·
August 6, 2025
Dexmedetomidine demonstrated a significant reduction in stress-induced behaviors, suggesting potential applications of BXCL501 in chronic psychiatric disorders in addition to treatment of acute agitation Leading academic institutions are evaluating BXCL- …
Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates
GlobeNewswire
·
August 6, 2025
Following FDA input, Seres submitted Phase 2 study protocol to FDA for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) to treat hematological malignancies Seres …
Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
August 6, 2025
– Submitted New Drug Application for vepdegestrant for the treatment of ESR1m, ER+/HER2- advanced or metastatic breast cancer – – Presented ARV-102 SAD and MAD data from the Phase 1 clinical trial in healthy volunteers; initiated dosing in patients with …
Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress
GlobeNewswire
·
August 6, 2025
– On track to report top-line data from Phase 2 trial in chronic rhinosinusitis with nasal polyps (CRSwNP) in the third quarter of 2025 – – Completed enrollment in Phase 2 trial in severe asthma in June 2025; top-line data expected in the first quarter of …
OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee
GlobeNewswire
·
August 6, 2025
PRESS RELEASE OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee Oxford, United Kingdom – 6th August 2025 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines …
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
GlobeNewswire
·
August 6, 2025
–European marketing authorization application on track in 2H25 – – PREVAIL Phase 3 CVOT remains on track – – Late Breaking BROADWAY and TANDEM data presented at EAS 2025 and simultaneously published in The New England Journal of Medicine (BROADWAY) and …
Entrada Therapeutics Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 6, 2025
-- First patient dosed in ELEVATE-44-201 with data from first patient cohort anticipated in H1 2026 -- -- Initiated ELEVATE-45-201 and on track to dose the first patient in Q3 2025 -- -- Multiple clinical trial sites in U.K. and EU activated for ELEVATE-44 …